Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.57 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | DRD3 | P35462 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | GPR183 | P32249 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3255524 | 0.91 | HRH4 (0.58) | KMT2ANPC1RAB9AHRH4DRD3 | |
| SCHEMBL3855664 | 0.88 | NPC1 (0.60) | KMT2ANPC1RAB9AHRH4DRD2 | |
| SCHEMBL3252765 | 0.85 | HRH4 (0.58) | KMT2ANPC1HRH4DRD3MEN1 | |
| SCHEMBL3254801 | 0.81 | KMT2A (0.44) | KMT2AHRH4DRD2DRD3MEN1 | |
| SCHEMBL3247041 | 0.80 | GPR183 (0.59) | KMT2AHRH4MEN1GPR183 | |
| SCHEMBL3257840 | 0.80 | KMT2A (0.60) | KMT2ANPC1RAB9ADRD2DRD3 | |
| SCHEMBL3255853 | 0.80 | IP6K1 (0.43) | HRH4GPR183 | |
| SCHEMBL2401624 | 0.79 | HRH4 (0.56) | KMT2ANPC1RAB9AHRH4DRD2 | |
| SCHEMBL3252852 | 0.78 | HRH4 (0.55) | HRH4DRD2DRD3 | |
| SCHEMBL3256593 | 0.76 | HRH4 (0.54) | HRH4DRD2DRD3GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202993-B2 | 5-bromo-1'-[(6-bromo-1H-indol-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | claimed |
| US-20080139553-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-12 | — | — | US | claimed |
| US-8202993-B2 | 5-bromo-1'-[(6-bromo-1H-indol-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202993-B2 | 5-bromo-1'-[(6-bromo-1H-indol-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202993-B2 | 5-bromo-1'-[(6-bromo-1H-indol-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| EP-2102207-B1 | SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-06-02 | — | — | EP | disclosed |
| EP-2102207-B1 | SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20080146568-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080146568-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080146568-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008068185-A1 | SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139554-A1 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139554-A1 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139553-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139554-A1 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139553-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139553-A1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139553-A1 | SPIRO-PIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | KMT2A 862/4885NPC1 2144/4885RAB9A 399/4885 |
| US-20080139554-A1 | SPIRO-PIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | KMT2A 862/4885NPC1 2144/4885RAB9A 399/4885 |
| US-20080146568-A1 | SPIRO-PIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | KMT2A 862/4885NPC1 2144/4885RAB9A 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.